Aspirin Protects Against Barrett's Esophagus in a Multivariate Logistic Regression Analysis

Published:March 19, 2012DOI:

      Background & Aims

      Better criteria are needed to identify patients who should be screened for Barrett's esophagus (BE) to reduce overtesting and improve the cost effectiveness. There is evidence that chemopreventive agents such as nonsteroidal anti-inflammatory drugs, particularly aspirin, reduce the risk of esophageal adenocarcinoma (EAC), but little is known about their effects on BE. We analyzed characteristics of patients with BE for factors that might be used in screening and management.


      In this case-controlled study, we identified 434 patients with BE diagnosed at the first endoscopy (incident cases) at a single institution (1997–2010). BE cases were matched with controls on the basis of indication for endoscopy, year of endoscopy, and endoscopist. Risk factors analyzed included age, sex, body mass index, medical and social history, and medications. We performed a multivariate logistic regression analysis to identify clinical risk factors for BE.


      In a multivariate regression model, men had a greater risk for developing BE (odds ratio, 3.2; 95% confidence interval, 2.3–4.4), whereas current aspirin users had a lower risk than nonusers (odds ratio, 0.56; 95% confidence interval, 0.39–0.80). A subset analysis, limited to patients who had endoscopies for symptoms of gastroesophageal reflux disease, yielded similar findings. No interactions were found between aspirin use and smoking or use of acid-suppressive medications.


      In a case-controlled study of 434 patients with BE, current aspirin use appeared to reduce the risk of BE; previous studies associated aspirin use with a reduced risk of EAC. Although efforts were made to minimize biases in our analysis, the possibility of residual confounding remains.


      Abbreviations used in this paper:

      BE (Barrett's esophagus), BMI (body mass index), CI (confidence interval), COX-2 (cyclooxygenase-2), EAC (esophageal adenocarcinoma), EGD (esophagogastroduodenoscopy), GERD (gastroesophageal reflux disease), GI (gastrointestinal), IM (intestinal metaplasia), NSAID (nonsteroidal anti-inflammatory drug), OR (odds ratio), PPI (proton pump inhibitor)
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. American Cancer Society, ACS: cancer facts & figures 2012.
        American Cancer Society, Atlanta2012
        • Spechler S.J.
        Barrett's esophagus.
        Gastroenterologist. 1994; 2: 273-284
        • Wang K.K.
        • Sampliner R.E.
        Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus.
        Am J Gastroenterol. 2008; 103: 788-797
        • Inadomi J.M.
        • Sampliner R.
        • Lagergren J.
        • et al.
        Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis.
        Ann Intern Med. 2003; 138: 176-186
        • Provenzale D.
        • Schmitt C.
        • Wong J.B.
        Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk.
        Am J Gastroenterol. 1999; 94: 2043-2053
        • Ouatu-Lascar R.
        • Fitzgerald R.C.
        • Triadafilopoulos G.
        Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression.
        Gastroenterology. 1999; 117: 327-335
        • Neumann C.S.
        • Iqbal T.H.
        • Cooper B.T.
        Long term continuous omeprazole treatment of patients with Barrett's oesophagus.
        Aliment Pharmacol Ther. 1995; 9: 451-454
        • Lao-Sirieix P.
        • Roy A.
        • Worrall C.
        • et al.
        Effect of acid suppression on molecular predictors for esophageal cancer.
        Cancer Epidemiol Biomarkers Prev. 2006; 15: 288-293
        • Kastelein F.
        • Spaander M.C.
        • Biermann K.
        • et al.
        Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.
        Gastroenterology. 2011; 141 (quiz e13–e14): 2000-2008
        • Nguyen D.M.
        • Richardson P.
        • El-Serag H.B.
        Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus.
        Gastroenterology. 2010; 138: 2260-2266
        • Shirvani V.N.
        • Ouatu-Lascar R.
        • Kaur B.S.
        • et al.
        Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure.
        Gastroenterology. 2000; 118: 487-496
        • Morris C.D.
        • Armstrong G.R.
        • Bigley G.
        • et al.
        Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.
        Am J Gastroenterol. 2001; 96: 990-996
        • Corley D.A.
        • Kerlikowske K.
        • Verma R.
        • et al.
        Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis.
        Gastroenterology. 2003; 124: 47-56
        • Jankowski J.
        • Moayyedi P.
        Re: cost-effectiveness of aspirin chemoprevention for Barrett's esophagus.
        J Natl Cancer Inst. 2004; 96 (author reply 887): 885-887
        • Kandil H.M.
        • Tanner G.
        • Smalley W.
        • et al.
        Cyclooxygenase-2 expression in Barrett's esophagus.
        Dig Dis Sci. 2001; 46: 785-789
        • Abdalla S.I.
        • Sanderson I.R.
        • Fitzgerald R.C.
        Effect of inflammation on cyclooxygenase (COX)-2 expression in benign and malignant oesophageal cells.
        Carcinogenesis. 2005; 26: 1627-1633
        • Wilson K.T.
        • Fu S.
        • Ramanujam K.S.
        • et al.
        Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas.
        Cancer Res. 1998; 58: 2929-2934
        • Zimmermann K.C.
        • Sarbia M.
        • Weber A.A.
        • et al.
        Cyclooxygenase-2 expression in human esophageal carcinoma.
        Cancer Res. 1999; 59: 198-204
        • Piazuelo E.
        • Jimenez P.
        • Lanas A.
        COX-2 inhibition in esophagitis, Barrett's esophagus and esophageal cancer.
        Curr Pharm Des. 2003; 9: 2267-2280
        • Yachimski P.
        • Lee R.A.
        • Tramontano A.
        • et al.
        Secular trends in patients diagnosed with Barrett's esophagus.
        Dig Dis Sci. 2010; 55: 960-966
        • Naimi T.S.
        • Brewer R.D.
        • Mokdad A.
        • et al.
        Binge drinking among US adults.
        JAMA. 2003; 289: 70-75
        • Naimi T.S.
        • Brown D.W.
        • Brewer R.D.
        • et al.
        Cardiovascular risk factors and confounders among nondrinking and moderate-drinking U.S. adults.
        Am J Prev Med. 2005; 28: 369-373
        • Lieberman D.
        • Fennerty M.B.
        • Morris C.D.
        • et al.
        Endoscopic evaluation of patients with dyspepsia: results from the national endoscopic data repository.
        Gastroenterology. 2004; 127: 1067-1075
        • Ford A.C.
        • Forman D.
        • Reynolds P.D.
        • et al.
        Ethnicity, sex, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus.
        Am J Epidemiol. 2005; 162: 454-460
        • Cook M.B.
        • Wild C.P.
        • Forman D.
        A systematic review and meta-analysis of the sex ratio for Barrett's esophagus, erosive reflux disease, and nonerosive reflux disease.
        Am J Epidemiol. 2005; 162: 1050-1061
        • Labenz J.
        • Jaspersen D.
        • Kulig M.
        • et al.
        Risk factors for erosive esophagitis: a multivariate analysis based on the ProGERD study initiative.
        Am J Gastroenterol. 2004; 99: 1652-1656
        • Fass R.
        Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics.
        J Clin Gastroenterol. 2007; 41: 131-137
        • Adeniyi K.O.
        Gastric acid secretion and parietal cell mass: effect of sex hormones.
        Gastroenterology. 1991; 101: 66-69
        • Anderson L.A.
        • Johnston B.T.
        • Watson R.G.
        • et al.
        Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence.
        Cancer Res. 2006; 66: 4975-4982
        • Thrift A.P.
        • Pandeya N.
        • Smith K.J.
        • et al.
        The use of nonsteroidal anti-inflammatory drugs and the risk of Barrett's oesophagus.
        Aliment Pharmacol Ther. 2011; 34: 1235-1244